Simplification of ART

In a U.S. clinical trial, patients who had never failed ART and switched to once-daily efavirenz/tenofovir/FTC maintained virologic suppression at the same rate as those who continued their baseline regimens.

Combination antiretroviral therapy (ART) has dramatically reduced HIV-related morbidity and mortality, but pill burden and adverse effects continue to frustrate even the most adherent, successfully treated patients. Is simplification of ART to a once-daily, single-pill regimen a reasonable option for patients who are virologically suppressed on more-complicated regimens?

In this 48-week, multicenter, open-label trial, 306 patients who had viral loads <200 copies/mL on stable PI- or NNRTI-based ART were randomized to either stay on their baseline regimen or simplify to once-daily efavirenz/tenofovir/FTC (Atripla). Per study protocol, all patients were either receiving their first ART regimen or had documented virologic suppression on a PI-bas…

Reviewing Author

Sonia Nagy Chimienti, MD

Disclosures

Nothing to disclose

Sonia Nagy Chimienti, MD

Disclosures

Nothing to disclose

Simplification of ART

Topics

Reviewing Author